J'S Laboratories Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 24-10-2024
- Paid Up Capital ₹ 5.38 M
as on 24-10-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 122.34%
(FY 2023)
- Profit 156.98%
(FY 2023)
- Ebitda 104.03%
(FY 2023)
- Net Worth 1.67%
(FY 2023)
- Total Assets 4.08%
(FY 2023)
About J'S Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 5.38 M, as per Ministry of Corporate Affairs (MCA) records.
John Salvador and Richard Jalarnath serve as directors at the Company.
- CIN/LLPIN
U24232TN2004PTC052792
- Company No.
052792
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does J's Laboratories Private Limited offer?
J'S Laboratories Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Skin Lightening Drugs, Glutathione Injection, Pharmaceutical Syrup, Vitamin Tablets & Capsules, Alcohol Solvents, Diacetone Alcohol, Plastic Film, Packaging Materials.
Who are the key members and board of directors at J'S Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
John Salvador  | Managing Director | 26-Dec-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Richard Jalarnath | Director | 16-Aug-2021 | Current |
Financial Performance of J'S Laboratories.
J'S Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 122.34% increase. The company also saw a substantial improvement in profitability, with a 156.98% increase in profit. The company's net worth moved up by a moderate rise of 1.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of J'S Laboratories?
In 2023, J'S Laboratories had a promoter holding of 47.44% and a public holding of 52.56%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
J's Living Space Private LimitedActive 16 years 6 monthsJohn Salvador and Richard Jalarnath are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at J'S Laboratories?
Unlock and access historical data on people associated with J'S Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of J'S Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped J'S Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
